Connecticut-based Wellinks offers integrated virtual care management for chronic obstructive pulmonary disease (COPD). Wellinks was established through a merger between ConvexityScientic Inc. and Wellinks in 2019. The company provides a medical kit including pulse oximeters, spirometers, and nebulizers that connect with its mobile app, enabling COPD patients and coaches to track health metrics in real-time. The company offers its US Food and Drug Administration (FDA) approved first pocket-portable nebulizer, Flyp Nebulizer, for patients’ breathing treatments. The app also offers regular feedback from coaches and personalized insights.
In November 2021, Wellinks raised USD 25 million in a Series C funding round led by Morningside Venture Investments. The funds will be used to pursue partnerships with payers and healthcare providers, expand its team, and invest in its new research studies on the platform’s clinical and economic outcomes.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.